BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback